A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
Rotavirus Vaccine
Infections, Rotavirus
Phase 3
The results of this study 107072 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014